@NICEComms @ERSpublications @LondonAsthma We had to wait 10 years but in 2015 Mepoluzimab was licenced for severe eosinophilic #asthma. It's an anti IL-5 MAb. IL-5 is crucial for development, migration & survival of eosinophils. Mepo reduces blood &am
RT @science_erik: ‘Severe eosinophilic #asthma: from the pathogenic role of interleukin-5 to the therapeutic action of #mepolizumab’ an #Op…
RT @science_erik: ‘Severe eosinophilic #asthma: from the pathogenic role of interleukin-5 to the therapeutic action of #mepolizumab’ an #Op…
‘Severe eosinophilic #asthma: from the pathogenic role of interleukin-5 to the therapeutic action of #mepolizumab’ an #OpenAccess article on #ScienceOpen #Pharmacology: https://t.co/HU0AC4svbb
RT asthma_papers "Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. https://t.co/512r7Uxuvq"
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. https://t.co/3i3sPdj02p
FYI.... https://t.co/pZjm9Ur8XJ